Moderna (LIM:MRNA) Institutional Ownership : 47.83% (As of Apr. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Moderna's institutional ownership is 47.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Moderna's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Moderna's Float Percentage Of Total Shares Outstanding is 75.91%.

Moderna Institutional Ownership Historical Data

The historical data trend for Moderna's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Institutional Ownership Chart

Moderna Historical Data

The historical data trend for Moderna can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	45.54	45.73	45.99	46.71	43.41	43.71	46.64	46.63	46.45	47.83

Moderna Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Moderna (LIM:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LIM:MRNA) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.